J-Pharma Co., Ltd. is a Japanese pharmaceutical company founded on December 26, 2005, and headquartered in Tokyo, Japan. The company specializes in drug discovery and development, focusing on solute carrier (SLC) transporters, particularly the LAT1 amino acid transporter. J-Pharma aims to develop innovative pharmaceuticals to address unmet medical needs, with ongoing projects including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company's operations include conducting functional and structural analyses of SLC transporters, collaborating with academic institutions, and participating in joint research efforts. As of March 31, 2026, J-Pharma had a capital stock of 2,033 million yen and employed 18 staff. The CEO, Masuhiro Yoshitake, has over 40 years of industry experience. J-Pharma was listed on the Tokyo Stock Exchange Growth Market on March 25, 2026, under the ticker symbol 520A.
AI-researched from public web sources — may contain errors or omissions and is not a substitute for verifying independently.
J-Pharma Co.,Ltd.'s offering is currently listed on JPX. The expected date is Mar 25, 2026. Shares are expected to be offered at ¥880 (~$5.87 USD), with 3.2M shares on offer. The proposed ticker is 520A. J-Pharma Co.,Ltd. is headquartered in Japan. It is classified under Biotech.
The dates below are calculated from widely-used industry conventions, not from this offering's own disclosed terms — DiscoverIPO does not have a structured source for the actual figures. Treat them as reference points, not confirmed dates.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with J-Pharma Co.,Ltd..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/j-pharma" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="J-Pharma Co.,Ltd. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/j-pharma?theme=light as the src instead.
https://www.discoveripo.com/ipo/j-pharma/opengraph-image
J-Pharma Co.,Ltd. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/j-pharma?utm_source=embed&utm_medium=text&utm_campaign=j-pharma
Get emailed when J-Pharma Co.,Ltd.'s terms, price, or expected date change — no weekly noise, just this company.
J-Pharma Co.,Ltd. is expected to list on Mar 25, 2026.
J-Pharma Co.,Ltd. is listing on JPX.
J-Pharma Co.,Ltd.'s proposed ticker is 520A.
J-Pharma Co., Ltd. is a Japanese pharmaceutical company founded on December 26, 2005, and headquartered in Tokyo, Japan. The company specializes in drug discovery and development, focusing on solute carrier (SLC) transporters, particularly the LAT1 amino acid transporter. J-Pharma aims to develop innovative pharmaceuticals to address unmet medical needs, with ongoing projects including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company's operations include conducting functional and structural analyses of SLC transporters, collaborating with academic institutions, and participating in joint research efforts. As of March 31, 2026, J-Pharma had a capital stock of 2,033 million yen and employed 18 staff. The CEO, Masuhiro Yoshitake, has over 40 years of industry experience. J-Pharma was listed on the Tokyo Stock Exchange Growth Market on March 25, 2026, under the ticker symbol 520A.
Japan Exchange Group new-listings page. Retrieved Aug 3, 2026.
View the original filing on JPX →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy